Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin G Bitler

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology Reports|April 9, 2024
Ovarian cancer think tank: An overview of the current status of ovarian cancer screening and recommendations for future directionsJulia M Dexter, Lindsay W Brubaker, Benjamin G Bitler, et al.
Nature Communications|October 10, 2018
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cellsShuai Wu, Nail Fatkhutdinov, Takeshi Fukumoto, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Cross-assay RNA modeling reveals cancer biomarkersHope A Townsend, Kimberly R Jordan, Rebecca J Wolsky, et al.
Cell Reports|September 15, 2016
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 ExpressionHengrui Zhu, Fee Bengsch, Nikolaos Svoronos, et al.
The Journal of Cell Biology|November 2, 2016
HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene lociKatherine M Aird, Osamu Iwasaki, Andrew V Kossenkov, et al.
Scientific Reports|October 5, 2018
CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancerBipradeb Singha, Sandra L Harper, Aaron R Goldman, et al.
Oncogene|November 9, 2024
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicityAngelica Escoto, Ryan Hecksel, Chance Parkinson, et al.
Expert Opinion on Therapeutic Targets|May 27, 2023
Novel chromobox 2 inhibitory peptide decreases tumor progressionLindsay W Brubaker, Donald S Backos, Vu T Nguyen, et al.
Nature Medicine|February 17, 2015
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersBenjamin G Bitler, Katherine M Aird, Azat Garipov, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinomaLucy Van Kleunen, Mansooreh Ahmadian, Miriam D Post, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology Reports|April 9, 2024
Ovarian cancer think tank: An overview of the current status of ovarian cancer screening and recommendations for future directionsJulia M Dexter, Lindsay W Brubaker, Benjamin G Bitler, et al.
Nature Communications|October 10, 2018
SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cellsShuai Wu, Nail Fatkhutdinov, Takeshi Fukumoto, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Cross-assay RNA modeling reveals cancer biomarkersHope A Townsend, Kimberly R Jordan, Rebecca J Wolsky, et al.
Cell Reports|September 15, 2016
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 ExpressionHengrui Zhu, Fee Bengsch, Nikolaos Svoronos, et al.
The Journal of Cell Biology|November 2, 2016
HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene lociKatherine M Aird, Osamu Iwasaki, Andrew V Kossenkov, et al.
Scientific Reports|October 5, 2018
CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancerBipradeb Singha, Sandra L Harper, Aaron R Goldman, et al.
Oncogene|November 9, 2024
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicityAngelica Escoto, Ryan Hecksel, Chance Parkinson, et al.
Expert Opinion on Therapeutic Targets|May 27, 2023
Novel chromobox 2 inhibitory peptide decreases tumor progressionLindsay W Brubaker, Donald S Backos, Vu T Nguyen, et al.
Nature Medicine|February 17, 2015
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersBenjamin G Bitler, Katherine M Aird, Azat Garipov, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinomaLucy Van Kleunen, Mansooreh Ahmadian, Miriam D Post, et al.
Pageof 12